Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation
批准号:
10596154
负责人:
TAHSEEN MOZAFFAR
金额:
$96.03万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-04-01 至 2026-03-31
关键词:
AddressAdoptedAgeAgingAmericanAntibodiesAntigensApoptosisBehaviorBiological MarkersBiopsy SpecimenBloodCD44 geneCellsClinical TrialsCommunitiesDataDevelopmentDiseaseDisease ProgressionEnrollmentEvaluationFrequenciesFutureGenerationsGeographic LocationsGoalsHistologyImmuneImmunohistochemistryImmunologicsImmunophenotypingImmunosuppressive AgentsInstitutional Review BoardsKnowledgeKv1.3 potassium channelLymphocyteLymphocyte SubtypingsMeasuresMediatingMolecularMorbidity - disease rateMorphologyMuscleMuscle WeaknessMyositisNatural HistoryNatural Killer CellsObservational StudyPathologyPatientsPatternPopulationPrevalenceProspective StudiesRare DiseasesResistanceRespiration DisordersRespiratory FailureRespiratory InsufficiencyRespiratory physiologySerologySerumSeverity of illnessSiteSkeletal MuscleSleep Apnea SyndromesSporadic Inclusion Body MyopathySubgroupSurveysT-LymphocyteTimeUnited StatesVariantclinical phenotypecohortcommunity engagementcytokinecytotoxicdesigndisabilitydisease natural historydisease phenotypefollow-upinterestpatient subsetspharmacologicprospectiverespiratorytargeted treatmenttreatment centertrial designwillingness
中文摘要
项目摘要
散发性包涵体肌炎(sIBM)是美国老年人的一种罕见疾病,
虚弱和严重残疾及发病。它目前无法治疗,而且人们对其了解甚少。的
sIBM的患病率可能会随着美国65岁以上人口的比例增加而增加
年继续增长。sIBM临床试验的一个主要障碍是缺乏对
疾病的自然史。疾病进展的速度是否一致还有待确定
以及是否与sIBM相关的各种生物标志物(抗NT5c1A抗体,变异T细胞群)
影响自然史和疾病行为。鉴于疾病进展缓慢,
不能在常规临床试验的背景下进行观察,此类研究需要作为一种
单独的独立观察性研究。为了解决这些未满足的需求,我们提出了一项前瞻性研究,
有四个具体目标。目的1:首次确定c1A抗体是否介导疾病
在sIBM患者中,两年内的进展。目的2:进行详细的形态学,
组织化学和免疫组织化学分析的新鲜肌肉活检标本获得的一个子集,
sIBM患者目的3:研究"免疫衰老"淋巴细胞在循环中的分布特点,
sIBM患者的血液。目的4:量化sIBM患者呼吸功能的下降。的
我们提出的研究的意义是:1)允许详细描述疾病进展,
sIBM在一个为期两年的时间,和2)探索的关系,一些生物标志物与
sIBM及其对疾病行为和疾病进展的影响。在实现这些目标后,我们
将1)了解疾病表型,包括呼吸系统受累模式,以及疾病
更好地了解NT5c1A抗体的血清抗体对sIBM进展的影响,
自然史和疾病行为; 2)定义血清变体T细胞和细胞因子特征的差异,
sIBM患者及其对疾病进展和行为的影响;以及3)了解肌肉病理学
sIBM患者的免疫细胞分布及其与NT5c1A抗体的关系。这些发现可能
影响sIBM未来试验设计。最后,我们将创建一个13个位点的肌炎联合体,
治疗中心,将准备迅速采用任何未来的临床试验,旨在改变的过程中,
sIBM。
英文摘要
PROJECT SUMMARY
Sporadic inclusion body myositis (sIBM) is a rare disorder of aging Americans, causing asymmetric muscle
weakness and severe disability and morbidity. It is currently untreatable, and poorly understood. The
prevalence of sIBM is likely to increase as the proportion of the United States population above the age of 65
years continues to grow. A major barrier to clinical trials in sIBM has been the lack of full understanding of the
natural history of the disease. It remains to be determined whether the rates of disease progression is uniform
and whether the various biomarkers associated with sIBM (anti-NT5c1A antibodies, variant T-cell populations)
influence the natural history and disease behavior. Given the slow rate of disease progression, such
observations cannot be made in the context of a routine clinical trial, and such studies need to be done as a
separate stand-alone observational study. To address these unmet needs, we propose a prospective study
with four specific aims. Aim 1: To determine for the first time whether c1A antibodies mediate disease
progression over a two year interval in patients with sIBM. Aim 2: To perform a detailed morphological,
histochemical, and immunohistochemical analysis of fresh muscle biopsy specimens obtained from a subset of
patients with sIBM. Aim 3: To characterize the distribution of “immunosenescent” lymphocytes in circulating
blood from patients with sIBM. Aim 4: To quantify the decline in the respiratory function of sIBM patients. The
significance of our proposed study is 1) to allow for a detailed characterization of the disease progression in
sIBM over a two-year period, and 2) to explore the relationship of a number of biomarkers associated with
sIBM, and their influence on disease behavior and disease progression. Upon completion of these aims, we
will 1) understand the disease phenotype, including pattern of respiratory involvement, and disease
progression in sIBM better and understand the influence of serum antibodies to NT5c1A antibodies on the
natural history and disease behavior; 2) define differences in serum variant T-cells and cytokine signatures in
sIBM patients and their influence on disease progression and behavior; and 3) understand muscle pathology
and immune cell distribution in sIBM patients and its relationship to NT5c1A antibodies. These findings may
influence future trial design in sIBM. Finally, we will have created a thirteen-site consortium of myositis
treatment centers that will be ready to adopt quickly any future clinical trials aimed at changing the course of
sIBM.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?
随机森林:对于面肩肱型肌营养不良症患者来说是随机结果还是有意义的见解?
DOI:
10.1093/brain/awab389
发表时间:
2021
期刊:
Brain : a journal of neurology
影响因子:
--
作者:
[Alfano,LindsayN, Mozaffar,Tahseen]
通讯作者:
Mozaffar,Tahseen
DOI:
10.1016/j.nmd.2022.08.005
发表时间:
2022-10
期刊:
NEUROMUSCULAR DISORDERS
影响因子:
2.8
作者:
[Goyal, Namita A., Greenberg, Steven A., Cauchi, Jonathan, Araujo, Nadia, Li, Vivian, Wencel, Marie, Irani, Tyler, Wang, Leo H., Palma, Anton M., Villalta, S. Armando, Mozaffar, Tahseen]
通讯作者:
Mozaffar, Tahseen
DOI:
10.1002/mus.27482
发表时间:
2022-03
期刊:
Muscle & nerve
影响因子:
3.4
作者:
[Avelar J, Wencel M, Chumakova A, Mozaffar T]
通讯作者:
Mozaffar T
Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview.
庞贝疾病:一种临床,诊断和治疗性概述。
DOI:
10.1007/s11940-022-00736-1
发表时间:
2022-11
期刊:
CURRENT TREATMENT OPTIONS IN NEUROLOGY
影响因子:
2
作者:
[Stevens, David, Milani-Nejad, Shadi, Mozaffar, Tahseen]
通讯作者:
Mozaffar, Tahseen
DOI:
10.1097/wco.0000000000001095
发表时间:
2022-10-01
期刊:
Current opinion in neurology
影响因子:
4.8
作者:
[]
通讯作者:
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation
-
批准号:10381454
-
项目类别:
-
资助金额:$115.9万
-
财政年份:2021
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
UCI-NEXT, a NeuroNEXT site
-
批准号:10192846
-
项目类别:
-
资助金额:$30.9万
-
财政年份:2018
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
UCI-NEXT, a NeuroNEXT site
-
批准号:9983184
-
项目类别:
-
资助金额:$30.9万
-
财政年份:2018
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
UCI-NEXT, a NeuroNEXT site
-
批准号:10407606
-
项目类别:
-
资助金额:$30.9万
-
财政年份:2018
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
A MULTICENTER STUDY FOR THE VALIDATION OF ALS BIOMARKERS
-
批准号:8166934
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2009
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY
-
批准号:7725027
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2007
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
A MULTI-CENTER, PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, CLINIC
-
批准号:7724999
-
项目类别:
-
资助金额:$0.14万
-
财政年份:2007
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
COMBINATION DRUG SELECTION TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS
-
批准号:7725029
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2007
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
A MULTICENTER, DOSE RANGING SAFETY AND PHARMACOKINETICS STUDY OF ARIMOCLOMOL IN)
-
批准号:7606647
-
项目类别:
-
资助金额:$2.02万
-
财政年份:2006
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
COMBINATION DRUG SELECTION TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS
-
批准号:7606663
-
项目类别:
-
资助金额:$0.85万
-
财政年份:2006
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY
-
批准号:7606659
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2006
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
AMYOTROPHIC LATERAL SCLEROSIS RESEARCH GROUP [ALS RG] COLLECTION OF DATA AND BI
-
批准号:7606658
-
项目类别:
-
资助金额:$1.67万
-
财政年份:2006
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
A MULTI-CENTER, PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, CLINIC
-
批准号:7606629
-
项目类别:
-
资助金额:$4.3万
-
财政年份:2006
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
RESEQUENCING THE VARIABLE HUMAN GENOME IN SPORADIC ALS: A NECESSARY PRELUDE TO
-
批准号:7606662
-
项目类别:
-
资助金额:$1.01万
-
财政年份:2006
-
负责人:TAHSEEN MOZAFFAR
-
依托单位:
海外基金